Economist Peter Schiff is calling out what he sees as hypocrisy among Republicans after President Donald Trump threatened to go after insurance companies over high prices.
Schiff took to X to criticize Trump for promising to pressure insurers into cutting prices, comparing it to proposals often made by progressive lawmakers.
“Donald Trump decided that insurance companies are making too much money, so he wants to use government power to force them to lower their prices,” Schiff wrote.
“If socialists @SenSanders, @ZohranKMamdani, or @AOC made similar threats, Republicans would rightly be up in arms. Why the hypocrisy?”
The comment sparked debate online, with one person asking, “Where is the hypocrisy when people can’t afford the prices?”
Schiff responded, “The hypocrisy is criticizing socialism when Democrats propose it but not when Republicans do. The reason prices are too high is because of government. We need capitalism to bring them down.”
Schiff clarified that Trump wasn’t just talking about health insurance, but all types of coverage, including auto and homeowners insurance.
“He wants to target all insurance, not just health,” he said in another reply.
While Schiff framed the president’s actions as government overreach, others online expressed frustration with the current insurance system, calling it unaffordable or even a “scam.”
Trump Expands Drug Pricing Push
The insurance comments came just as Trump announced new drug pricing deals.
Last Friday, the president revealed that nine more pharmaceutical companies had signed agreements to lower prices in exchange for a three-year break from tariffs, according to NCPA.
The deals are part of Trump’s push to lower drug costs under his TrumpRx program, set to launch next year.
Fourteen of the 17 drugmakers he targeted have now agreed to provide cheaper medication for Medicaid and sell discounted drugs directly to consumers paying out of pocket.
The latest companies to sign on include Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi. They join Pfizer, AstraZeneca, EMD Serono, Eli Lilly, and Novo Nordisk.
Trump said the companies agreed to launch new medicines at the same price as in other countries under his “Most Favored Nation” pricing system.
That leaves three holdouts: AbbVie, Johnson & Johnson, and Regeneron. Trump said he expects them to come to the table soon after the holidays.
Insurance Industry in the Crosshairs
Trump closed the press announcement with a promise to meet with the “big, rich insurance companies,” who he said make “far, far more money than they’re entitled to.”
He said meetings will be held either in Florida next week or in Washington, D.C., during the first week of January to push for price cuts of 50 to 70 percent.
He added that the money should go “directly to the people” and warned that insurance companies could be cut out of the system entirely if they refuse to cooperate.
According to NCPA, Trump emphasized that insurance companies would need to participate in cost-cutting reforms or risk losing their role in the system.
This aggressive stance drew Schiff’s criticism, but also praise from Trump supporters who see the moves as consumer-friendly.
Who Deserves the Credit?
Some online responses argued that Trump isn’t breaking new ground, but rather enforcing cost controls already put in place by previous administrations.
While opinions remain split, Schiff’s central argument is about consistency. He believes Republicans shouldn’t support government price controls when it’s politically convenient.
As Trump ramps up efforts to reshape the healthcare and insurance sectors going into the election year, his populist message appears to be resonating with a segment of the public tired of high prices and corporate profits.
But for critics like Schiff, the concern is that government intervention, regardless of who’s in charge, risks moving the country away from free-market principles.
IMAGE CREDIT: “Peter Schiff” by Gage Skidmore, via Flickr. Licensed under CC BY-SA 2.0. Image adjusted for layout.